tambotatug pelitecan + toripalimab

YL201 + toripalimab is an investigational combination regimen consisting of tambotatug pelitecan (YL201), a B7-H3-targeted antibody-drug conjugate (ADC), and toripalimab, a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1). Tambotatug pelitecan utilizes MediLink's TMALIN platform to link a B7-H3-specific antibody to a topoisomerase I inhibitor payload, enabling dual-release of the cytotoxic payload both intracellularly and extracellularly in the tumor microenvironment. Toripalimab acts as an immune checkpoint inhibitor, blocking the interaction of PD-1 with its ligands PD-L1 and PD-L2 to restore T-cell-mediated antitumor activity. The combination is being evaluated in a Phase 1/2 clinical trial (NCT07258979) in China for the treatment of recurrent or metastatic nasopharyngeal carcinoma, administered with or without cisplatin.